Skip to main content

ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy

Written by Customer Service on . Posted in Public Companies.

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) —

When:          May 17–22, 2024
Where:         San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101
                       Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101

Research:     26 ResMed-supported abstracts will be presented at ATS. Full list below. Highlights:

  • Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilation (READ-ASV)
    in Opioid Users – a European Registry
    • Sunday May 19, 2024, 9:15 a.m. – 11:15 a.m., SDCC 32A-B
    • Presented by Jean-Louis Pepin, MD, Grenoble Alpes University, France
  • An Estimate of the Prevalence of Obstructive Sleep Apnea in the United States into 2050
    • Monday, May 20, 9:15 a.m. – 4:15 p.m., SDCC Area C Hall A-B2
    • Presented by Elroy Boers, PhD, ResMed Science Center
  • All-Cause Mortality in Obstructive Sleep Apnea
    • Monday, May 20, 2:15 p.m. – 4:15 p.m., SDCC 32A-B
    • Presented by Atul Malhotra, MD, University of California, San Diego
  • Impact of Positive Airway Pressure (PAP) Therapy on Hospitalization in Obstructive Sleep Apnea (OSA): Analysis of a German Healthcare Database
    • Monday, May 20, 2:15 p.m. – 4:15 p.m., SDCC 32A-B
    • Presented by Holger Woehrle, MD, Ulm Lung Centre, Germany
  • Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilation – Outcomes in Patients with Treatment-Emergent or Persistent Central Sleep Apnea
    • Tuesday, May 21, 2:15 p.m. – 4:15 p.m., Marriott Marquis Pacific Ballroom 15-17
    • Presented by Michael Arzt, MD, Universitätsklinikum Regensburg, Germany

Innovation Hub:     Healthcare of Today, Looking Towards Tomorrow: Digital Innovations and Patient Centricity

  • Monday, May 20, 1:15 – 1:35 p.m., SDCC Innovation Hub 4
  • Presented by Monica Mallampalli, Chief Executive Officer at Alliance of Sleep Apnea Partners, and Carlos Nunez, ResMed Chief Medical Officer

Booth #1442:            Featuring ResMed’s latest innovations in respiratory care:

  • AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
  • AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask

Complete list of ResMed sponsored studies to be presented at ATS 2024:

Treatment of sleep-disordered breathing with adaptive servo-ventilation (READ-ASV) in opioid users – a European registrySunday, May 19, 2024
9:15 AM -11:15 AM
8-year Trends in Obesity, Type 2 Diabetes, and Glucagon-like Peptide-1 (GLP-1) Use in Patients With Obstructive Sleep ApneaSunday May 19, 2024
9:15 AM – 11:15 AM
Impact of CPAP Termination on Permanent Work Disability in Obstructive Sleep Apnea: A French Nationwide Alaska Database AnalysisSunday May 19, 2024
9:15 AM – 4:15 PM
Tailoring Social Support to Improve PAP Therapy Usage in Obstructive Sleep ApneaSunday May 19, 2024
9:15 AM – 4:15 PM
Examining Alignment of Patient Medication-taking Behaviors With Inhaler Usage Recommendations in Chronic Obstructive Pulmonary Disease and AsthmaSunday May 19, 2024
9:15 AM – 4:15 PM
Using Natural Language Processing for Qualitative Research: Insights From a Real-world AnalysisSunday May 19, 2024
9:15 AM – 4:15 PM
A Qualitative Analysis of Perceptions and Awareness of Air Pollution and Its Health Effects in Asthma Among Asthma-care Professionals Across Southern CaliforniaMonday May 20, 2024
9:15 AM – 4:15 PM
An Estimate of the Prevalence of Obstructive Sleep Apnea in the United States Into 2050Monday May 20, 2024
9:15 AM – 4:15 PM
All-cause Mortality in Obstructive Sleep Apnea: Systematic Literature Review Including Randomised Trials and Confounding Adjusted Non-randomised Controlled Studies and Meta-analysis of Positive Airway Pressure TreatmentMonday May 20, 2024
2:15 PM – 4:15 PM
Impact of Positive Airway Pressure (PAP) Therapy on Hospitalization in Obstructive Sleep Apnea (OSA): Analysis of a German Healthcare DatabaseMonday May 20, 2024
2:15 PM – 4:15 PM
Hypoxic Burden but Not AHI Predicts Risk of Cardiovascular Events: A Secondary Analysis of the RICCADSA Clinical TrialMonday May 20, 2024
2:15 PM – 4:15 PM
A Digital Quality Improvement Program Delivered By Clinical Pharmacists Can Reduce Acute Care Visits In COPDMonday May 20, 2024
2:15 PM – 4:15 PM
Hands-on Simulation Training With Home Ventilators Improves PCCM Fellow Understanding of Nocturnal NIV in Chronic HypercapniaMonday May 20, 2024
2:15 PM – 4:15 PM
The Economic and Health Burden of COPD in North America Through 2050: A Scenario Analysis Based on Two Large Data SourcesTuesday May 21, 2024
9:15 AM – 11:15 AM
Impact of long-term domiciliary noninvasive ventilation (NIV) on severe exacerbations and survival in Patients with Chronic Obstructive Pulmonary Disease (COPD): a nationwide cohort study using multistate modelsTuesday May 21, 2024
9:15 AM – 11:15 AM
Nocturnal Hypoxemic Burden and Micro- and Macrovascular Disease in Patients With Type 2 DiabetesTuesday May 21, 2024
9:15 AM – 11:15 AM
Risk Factors for Severe Exacerbation Occurrence Among Patients With COPD-OSA Overlap Syndrome Using Bilevel Positive Airway Pressure TherapyTuesday May 21, 2024
9:15 AM – 4:15 PM
Adherence to Glucagon-like Peptide-1 Receptor Agonists (GLP-1s) in Obstructive Sleep Apnea Patients With and Without Type 2 DiabetesTuesday May 21, 2024
2:15 PM – 4:15 PM
Treatment of sleep-disordered breathing with adaptive servo-ventilation (READ-ASV) – outcomes in patients with treatment-emergent or persistent central sleep apnea (TE-CSA) in a European registryTuesday, May 21, 2024
2:15 PM – 4:15 PM
A Scenario-based Modeling Study to Project the Future Burden of COPD in the United States Accounting for the Effects of E-cigarettesTuesday May 21, 2024
2:15 PM – 4:15 PM
The Impact Of Weight Change On Positive Airway Pressure Use In Patients With Obstructive Sleep Apnea And ObesityTuesday May 21, 2024
2:15 PM – 4:15 PM
Real World GLP-1 Adherence in Patients with Treated Obstructive Sleep ApneaTuesday May 21, 2024
2:15 PM – 4:15 PM
Less REM Sleep Predicts Mortality in Adults With Coronary Artery Disease and Obstructive Sleep Apnea: The RICCADSA TrialTuesday May 21, 2024
2:15 PM – 4:15 PM
Gender Specific Differences in a National Sample of Individuals with Comorbid Insomnia, Obstructive Sleep Apnea (OSA), and DepressionWednesday May 22, 2024
8:15 AM – 10:15 AM
Use of Weight Management Regimens Among Positive Airway Pressure-Treated Patients With Obstructive Sleep Apnea and ObesityWednesday May 22, 2024
11:00 AM – 1:00 PM
A Mixed-methods Exploration of Patient Perspectives on Pap Therapy Initiation: Implications for Improved Outreach and EducationWednesday May 22, 2024
11:00 AM – 1:00 PM


CONTACT: Media questions/requests:        
Peter Duckler, +1 (773) 343-3069, pduckler@realchemistry.com
Rowena Kelley, +1 (858) 289-7272, rowena.kelley@resmed.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.